Holen Sie sich die Stockscreener-App
4.265
0.35%
0.015
Vorhandelsmarkt:
4.37
0.105
+2.46%
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing - Stock Titan
Coya Therapeutics Inc (COYA) Balance Sheet - TradingKey
Coya Therapeutics Inc (COYA) Cash Flow - TradingKey
COYA|Coya Therapeutics Inc|Price:4.250|Chg%:-0.130 - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Coya Therapeutics Market Sentiment - Benzinga España
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Income Statement - TradingKey
Coya Therapeutics, Inc. Revenue Breakdown – NASDAQ:COYA - TradingView
Coya Therapeutics Inc (COYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to earnings forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to sales forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Coya Therapeutics (COYA) Dips 1.3% as Stock Tests Key Support LevelsBear Pennant - dars.gov.et
Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target - Streetwise Reports
Houston ALS Biotech Coya Eyes 2028 Approval Path - Streetwise Reports
Coya Therapeutics(COYA) Stock Options Chain | Quotes & News - Moomoo
Coya Therapeutics (COYA) Slips 1.87% as Stock Tests Key Support Near $5.00Triple Top - dars.gov.et
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - AOL.com
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline AdvancesProfitability Analysis - dars.gov.et
Roth MKM Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Coya Therapeutics Dips 2.3% as Stock Tests Key Support at $5.42Max Pain Level - dars.gov.et
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Behavioral Patterns of COYA and Institutional Flows - Stock Traders Daily
Coya Therapeutics, Inc. Actuals & Estimates (NASDAQ:COYA) - TradingView
Coya Therapeutics, Inc. Actuals & Estimates (BOATS:COYA) - TradingView
Coya Therapeutics Price Target Maintained With a $14.00/Share by Chardan Capital - Moomoo
H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA) - The Globe and Mail
Coya Therapeutics, Inc. Reports 2026 Annual Meeting Results and Company Information (NASDAQ: COYA) - Minichart
Coya Therapeutics Shareholders Back Board, Auditor at Meeting - TipRanks
Coya Therapeutics (NASDAQ: COYA) shareholders back board nominees and 2026 auditor - Stock Titan
COYA Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Coya Therapeutics (COYA) Investor update Summary - Quartr
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentEarnings Recovery Stocks - dars.gov.et
Number of shareholders of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
COYA Therapeutics Inc. (COYA) Edges Higher as Stock Hovers Near ResistanceRip Sell Trade - dars.gov.et
Exosomes Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO - Barchart.com
COYA Technical Analysis & Stock Price Forecast - Intellectia AI
COYA Q1 2026 Earnings: Wider-Than-Expected Loss Still Beats Estimates as Biotech Advances PipelineNext Quarter Guidance - dars.gov.et
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - BioSpace
Coya Therapeutics Inc (COYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Institutional Confidence - TradingKey
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
COYA Maintains Buy Rating by Chardan Capital -- Price Target at $14 - GuruFocus
Coya Therapeutics (COYA) Gains 2.16% as Stock Nears Key Resistance ZoneDip Buy Trade - newsline.com
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Coya Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact - Yahoo Finance
Coya Therapeutics begins extension phase of ALSTARS trial for COYA 302 - MSN
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase - BioSpace
COYA Q1 2026 Earnings: EPS Surprises Wall Street with Narrower Loss, Stock DeclinesAnnual Financial Report - newsline.com
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):